Spesolimab for the Treatment of Generalized Pustular Psoriasis Flares: An Observational, Retrospective, and Multicenter Study of Effectiveness and Safety in Real‐World Clinical Practice
Year: 2025
Type: article
Study design: Observational Study
Abstract: FIGURE 1 | Response rates to spesolimab treatment at 16 weeks of follow-up, measured by the Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score (%).
DOI: 10.1111/ijd.17795
Authors: Elena Canal‐Garcia, Elena del Alcázar‐Viladomiu, Rosa María Izu, Mar Llamas‐Velasco, Javier Alcántara‐González, Adrián Ballano‐Ruiz, Tamara Gracia‐Cazaña, María García‐Sánchez, Amalia Pérez‐Gil, Juan Antonio Ratón‐Nieto, Raquel Rivera‐Díaz, Antonio Sahuquillo‐Torralba, Celia Sanchis‐Sánchez, José Manuel Carrascosa
Institutions: Universitat Autònoma de Barcelona, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Hospital de Basurto, Hospital Universitario de La Princesa, Hospital Universitario de Torrejón, Hospital Universitario del Henares, Hospital Universitario Miguel Servet, Complejo Asistencial Universitario de Palencia, Hospital Universitario de Valme, Hospital de Cruces, Hospital Universitario 12 De Octubre, Hospital Universitari i Politècnic La Fe
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4409566833